Diss. Linköping : Univ., 2003.

Besides collagen, elastin is the most common connective tissue structural protein in vertebrates and similar to collagen relatively resistant to non-specific degradation. Typical elastolytic proteases are the serine-dependent pancreatic and leukocyte elastases, the Zn-dependent matrix metalloproteinase 12, and several lysosomal cysteine proteases. Among the cysteine cathepsins, cathepsins S, K and V are highly potent elastases with cathepsin V displaying the highest activity among all known mammalian elastases. Despite a shared amino acid sequence identity of over 80% between cathepsins V and L and very similar subsite specificities, only cathepsin V has a potent elastase activity whereas cathepsin L lacks it. A series of chimera mutants containing various proportions of cathepsin V and cathepsin L were constructed in an attempt to define a specific region needed for elastin degradation. It was found that retaining the peptide sequence region from amino acids 89 to 119 of cathepsin V preserves the mutant’s elastolytic activity against elastin-Rhodamine conjugates whereas the region FTVVAPGK (amino acids 112-119) contributes approximately 60% of activity retention. Several additional mutant proteins involving mutual swapping of residues VDIPK (amino acids 113-117) of cathepsin L with residues TVVAPGK (amino acids 113-119) of cathepsin V, deletion of Glyl 18 from cathepsin V, and insertion of Gly between Prol 16 and Lysi 17 in cathepsin L were constructed and evaluated for their elastolytic activities. The results obtained with those mutant cathepsin proteins support the importance of the amino acid region spanning the residues from 112 to 119 in cathepsin V. Based on the 3-D structure of cathepsin V, this peptide region is located below subsite binding pocket S2 and forms a wall-like barrier which may act as an exosite for the productive binding of cross-linked elastin. / Medicine, Faculty of / Biochemistry and Molecular Biology, Department of / Graduate

Abstract The assay for the carboxyterminal telopeptide of type I collagen, ICTP, has been shown to be a reliable marker in many pathological conditions but insensitive to changes in physiological bone turnover. This has induced uncertainty and confusion regarding the role of ICTP assay in the study of collagen metabolism in bones. Especially, since another assay for the carboxyterminal telopeptide of type I collagen, serum CrossLaps ELISA, sensitively follows the changes in physiological bone turnover. To find out the reasons for the discrepancy we characterized the antigenic determinant of the ICTP assay by comparing human and bovine antigens after trypsin and chymotrypsin treatments. An assay for bovine ICTP was developed contemporarily with the present study. The epitope lies on the phenylalanine rich region of two telopeptide chains. We were able to show that the region is destroyed by cathepsin K, an osteoclastic enzyme responsible for physiological bone turnover, but not by several matrix metalloproteinases (MMPs), which are important collagen degrading enzymes in pathological conditions. Cathepsin K treatment had no effect on the CrossLaps assay. The CrossLaps assay is also able to measure the MMP-derived fragments, but usually their amount is so low in serum that it is masked by the cathepsin K-derived collagen degradation. The results explain the apparent discrepancy regarding the different behaviour of ICTP and CrossLaps assays in various conditions as also verified in our study with rheumatoid arthritis patients. The ICTP assay was also found to measure only trivalently cross-linked forms of the carboxyterminal telopeptide which contains two telopeptide chains, and is therefore unable to react with divalently or histidinohydroxylysinonorleucine (HHL)-cross-linked forms of the carboxyterminal telopeptide. These forms can be measured with the SP4 (synthetic peptide 4) assay. We utilized this property in analyzing the skin samples of 18 breast cancer patients on both the irradiated and unirradiated side. The content of HHL was increased on the irradiated side, as were type I collagen synthesis and degradation. In conclusion, there are two assays for two different degradation products of the trivalently cross-linked carboxyterminal telopeptide of type I collagen, ICTP and CrossLaps, the former measuring the MMP-derived and the latter the cathepsin K-derived collagen degradation.

This document only includes an excerpt of the corresponding thesis or dissertation. To request a digital scan of the full text, please contact the Ruth Lilly Medical Library's Interlibrary Loan Department (rlmlill@iu.edu).

The main site for protein degradation along the endosomal pathway is believed to be the late endosome. Lysosomes are thought to be storage organelles that, when necessary, inject proteases into the late endosome. It was hypothesised that differences in the lumenal redox environments between the two organelles could be responsible for their functional differences. In an attempt to quantify this potential difference, the lysosomal cysteine protease cathepsin B was isolated by an improved purification procedure. Several intracellular reducing agents were used to activate cathepsin B, the most effective being cysteine. Cysteine was used to activate cathepsin B under various pH conditions in order to model endosomal conditions. An inverse relationship was found between the pH and the concentration of cysteine required to activate cathepsin B. This suggested that cathepsin B may have an optimal redox potential. In order to determine this potential, cysteinexystine redox buffers were made up and used in determination of the activity of the enzyme against a synthetic and a whole protein substrate (haemoglobin). No distinct redox potential could be determined using either substrate, but it was found that cystine stimulated proteolysis of haemoglobin. A similar stimulatory effect was observed for cathepsin D and papain hydrolysis of haemoglobin. This effect is possibly due to the ability of cystine to promote substrate structure, effectively increasing the substrate concentration. These findings and other results obtained from the literature have been used to create a model of how proteolysis may be regulated along the endosomal system. / Thesis (M.Sc.)-University of Natal, Pietermaritzburg, 1999.

The function of chitin binding protein (CBP) and two isoforms of cathepsin B (cathB1, cathB2) were tested by using RNA interference in the tick I. ricinus. Two different methods have been used to deliver dsRNA for RNAi in ticks {--} injection and capillary feeding. The synthesized dsRNA was used to find out the impact of RNAi in the tick tissues, which were tested by RT-PCR and Western blot. The expression of CBP was successfully silenced by RNAi in the salivary glands. The silencing of cathB1 and cathB2 in the gut was less effective, but still limited tick`s ability to feed.

Indiana University-Purdue University Indianapolis (IUPUI) / Many factors are present in the development of skeletal tissue. Some factors lead to an increase in bone mass while some lead to a decrease. One factor that is known to have an influence on skeletal development is Signal Transducer and Activator of Transcription 3 (Stat3). This knowledge arose because of a mutation in the Stat3 gene in humans causing a disease called Hyper-IgE Syndrome. This mutation leads to a variety of issues, including decreased bone mass. Because of this, our lab has sought to study Stat3 in its relation to bone. Many studies have already been conducted that discern how Stat3 influences skeletal biology by observing its role in osteoclasts, osteoblasts, and other bone cells. Its role is still unclear, and many studies have provided seemingly contradictory results in how it works on bone tissue. Our lab set up several different studies in order to further elucidate what role Stat3 plays in skeletal development by looking at its effects on osteoblasts and osteoclasts, the bone-forming and bone-destroying cells of the body, respectively. We conditionally knocked out Stat3 in the osteoblasts of mice and compared several different bone parameters to their wild type counterparts at 8 weeks of age. Differences were noted in bone phenotype, including decreased femur length, weight, bone mineral density, and bone mineral content in the cKO compared to their WT counterparts. While no significant difference in trabecular integrity was noted, several differences were observed in cortical bone. These differences indicate that Stat3 has a positive role in osteoblast differentiation, leading to an overall positive effect on bone mass. To observe the role of Stat3 in osteoclasts, in vitro experiments were set up in which pre-osteoclast RAW 264.7 cells were manipulated with Stat3 siRNA or a Stat3 overexpression construct and RANKL to induce differentiation. Using qPCR and western blot assays, it was determined that when Stat3 is knocked down, several important genes in osteoclastogenesis and osteoclast function are more highly expressed than in the control groups. When Stat3 is overexpressed, a similar pattern is observed where these same genes are downregulated in the presence of higher Stat3 levels. These results indicate that Stat3 has an overall inhibitory effect on osteoclastogenesis and osteoclast function, indicating it has a positive effect on bone mass. Future studies could be performed to further elucidate the effects of Stat3 on skeletal development. Isolating the osteoblasts from cKO and WT mice and performing qPCR and western blot assays could be useful in finding out how Stat3 is influencing these cells. Further studies could also be done on the RAW 264.7 cells to find where Stat3 is interacting with the RANKL pathway. A resorption assay could be done with these cells to better understand how function might be influenced by Stat3.

No / Whereas protease inhibitors have been developed successfully against hypertension and viral infections, they have failed thus far as cancer drugs. With advances in cancer profiling we now better understand that the tumor “degradome” (i.e. the repertoire of proteases and their natural inhibitors and interaction partners) forms a complex network in which specific nodes determine the global outcome of manipulation of the protease web. However, knowing which proteases are active in the tumor micro-environment, we may tackle cancers with the use of Protease-Activated Prodrugs (PAPs). Here we exemplify this concept for metallo-, cysteine and serine proteases. PAPs not only exist as small molecular adducts, containing a cleavable substrate sequence and a latent prodrug, they are presently also manufactured as various types of nanoparticles. Although the emphasis of this review is on PAPs for treatment, it is clear that protease activatable probes and nanoparticles are also powerful tools for imaging purposes, including tumor diagnosis and staging, as well as visualization of tumor imaging during microsurgical resections.

No description available.

The collagenolytic proteinases, type IV collagenase and cathepsins Land H, have been implicated in tumour invasion and metastasis, by virtue of their degradative action on the extracellular matrix barriers traversed by migrating tumour cells. Type IV collagenase was isolated from human leucocytes using anti-peptide antibody immunoaffinity chromatography. The highly specific targeting of both native and denatured forms of human type IV collagenase by these anti-peptide antibodies holds much promise for immunolocalisation studies in human tumour tissue. Cathepsin L was purified in both a free; single-chain form from sheep liver, and as complexes with the endogenous cysteine proteinase inhibitor, stefin B. These complexes comprised mixtures of the usual tight-binding non-covalent, inhibitory complexes, and novel, proteolytically active, covalent cathepsin L/stefin B complexes. The latter form spontaneously in a pH-dependent manner in vitro from purified, active constituents. The primary structures of these complexing moieties from sheep liver are reported here for the first time, and showed a high degree of sequence homology with their human counterparts. Single-chain cathepsin L, both in the free, and novel, covalently complexed forms, manifested stability and increased activity at neutral pH, thus suggesting a role in extracellular tissue destruction. This potential involvement in tumour invasion was strengthened by demonstrating that the single-chain form of the enzyme, and similar covalent complexes, active under physiological conditions, could be isolated from liver tissue homogenates of higher primates, baboon (Papio ursinus) and man. A battery of versatile polyclonal anti-sheep cathepsin L and anti-human cathepsins L and H peptide antibodies were raised in chickens and rabbits. The chicken egg yolk antibodies were often of a higher titre than the corresponding rabbit serum antibodies, and additionally manifested unique immunoinhibitory properties. In the case of the polyclonal chicken anti-sheep cathepsin L antibodies, this was derived from their ability to target a peptide located in the active site of cathepsin L. The chicken anti-human cathepsins L and H peptide antibodies constitute the immunological probes of choice for immunolocalisation and in vitro tumour invasion studies to elucidate the relative contributions of these collagenolytic cathepsins to tumour invasion, and could ultimately find application in tumour immunotherapy. / Thesis (Ph.D.)-University of Natal, Pietermaritzburg, 1992.